Posted by & filed under Company Analysis, Governments & Regulators, Growth & Valuation, Industry Analysis, Management Issues, Personal Finance.

Description: A third of development costs comes from clinical trials. Novartis wants to make them cheaper and faster.


Date: Jan 25, 2019


Questions for discussion:

  • Summarize the approach being developed to reduce and control expenses?
  • Why do you suppose it is only now being considered by these drug companies?
  • Should investors consider this as a factor when choosing any particular firm?

Leave a Reply

Your email address will not be published. Required fields are marked *